FACULTY

Prithviraj Bose, MD
Professor, Department of Leukemia
Chief, Section of Myeloproliferative Neoplasms
UT MD Anderson Cancer Center
Houston, Texas

Maximilian Stahl, MD
Assistant Professor
Director Leukemia and Myeloid Malignancy Program
Yale Cancer Center
Chief Duffy Hematology Firm
Yale-New Haven Hospital
New Haven, Connecticut

PROGRAM DESCRIPTION

This hybrid (online) Whiteboard Satellite Symposium at the annual meeting of the Society of Hematologic Oncology (SOHO 2025) will have two expert faculty leading this activity which will incorporate high-definition slides, interactive case studies, and an immersive whiteboard animation. The program seeks to highlight the latest updates to the clinical guidelines as well as bring the best practices for treatment sequencing of patients with anemia associated with MF to life. The program will also highlight new clinical data for anemia-targeting agents in MF as well as help identify the patients who would benefit most from anemia-sparing therapies.

TARGET AUDIENCE

This program is designed to address the educational needs of the multidisciplinary hematology-oncology team, including hematologists, pathologists, nurses, and other multidisciplinary healthcare professionals working together to address the needs of patients with anemia due to MF.

LEARNING OBJECTIVES

After completing this activity, the participant should be better able to:

• Summarize the updates to clinical guidelines and best practices informing treatment sequencing for patients suffering from anemia associated with MF.
• Assess the new clinical data for anemia targeting agents in MF.
• Identify patients who could benefit from frontline anemia-sparing therapies.

AGENDA

5 min.	Introduction and Pre-Test
15 min.	Didactic Content Shared by Faculty Using Slides and Infographic Data Current challenges and unmet needs in managing anemia in MF patients Emerging treatments for anemia in MF Guidelines and best practices for efficient anemia management in MF patients (LO#1 & 2) Updates to the MF clinical guidelines Discussing best practices to sequence the anemia treatment for MF patients Addressing the mitigation of the Adverse Events of anemia treatment in MF patients Data from the select clinical trials evaluating novel agents for the treatment of MF-associated anemia
5 min.	Whiteboard Animation & Analysis (embedded into didactic review above) Theme: Guidelines and best practices for efficient anemia management in MF patients (LO#1 & 2)
10 min.	Planning the best anemia treatment for your patient? (LO#3) Presence or absence of genomic alterations Comorbidities Other cotreatments Risk stratification Adverse Events Timing
15 min.	Case Study Discussion (sample case listed below) 68-year-old woman with intermediate-risk MF and worsening anemia requiring biweekly transfusions.
10 min.	Conclusions, Q&A, and Post-Test

ACCREDITATION, SUPPORT AND CREDIT

In support of improving patient care, Medical Learning Institute Inc is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION

Medical Learning Institute Inc (MLI) designates this virtual activity for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSING CONTINUING PROFESSIONAL DEVELOPMENT

Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour and 1.0 contact hour in the area of pharmacology.

COMMERCIAL SUPPORT STATEMENT

This educational activity is supported by an independent medical education grant from GSK.

DISCLOSURE & CONFLICT OF INTEREST POLICY

Medical Learning Institute Inc and Med Learning Group are committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.

FACULTY DISCLOSURES

Prithviraj Bose, MD
Professor, Department of Leukemia
Chief, Section of Myeloproliferative Neoplasms
UT MD Anderson Cancer Center
Houston, Texas

Dr. Bose has a financial interest/relationship or affiliation in the form of:
Consulting fees from Incyte, Bristol Myers Squibb (BMS), CTI, Morphosys, AbbVie, Cogent, Blueprint, Ionis, Disc, Geron, Karyopharm, Sumitomo, Keros, Merck, GSK, Takeda, Raythera, PharmaEssentia, Morphic, Jubilant, Novartis
Contracted research for Kartos, Telios, Ajax, and Janssen.
He also intends to reference unlabeled or unapproved uses of the following drugs or products in his presentation: danazol, thalidomide, lenalidomide, pomalidomide, luspatercept, elritercept, zilurgisertib, and DISC-0974.

Maximilian Stahl, MD
Assistant Professor
Director Leukemia and Myeloid Malignancy Program
Yale Cancer Center
Chief Duffy Hematology Firm
Yale-New Haven Hospital
New Haven, Connecticut

Dr. Stahl has a financial interest/relationship or affiliation in the form of:
Served on the advisory board for Novartis, Kymera, Sierra Oncology, GSK, Rigel, BMS, Sobi, Syndax, and Kura, and has also provided consulting services.

All of the relevant financial relationships of individuals for this activity have been mitigated.

PLANNING COMMITTEE AND CONTENT/PEER REVIEWERS

The planners and content/peer reviewers from Medical Learning Institute Inc, the accredited provider, and Med Learning Group, the educational partner, do not have any relevant financial relationships to disclose with ineligible companies.
La Donna Lue Winston has nothing to disclose.
Vaidehee Deshpande, Ph.D., Medical Director for Med Learning Group, has nothing to disclose.
Russie Allen, M.S., Accreditation & Outcomes Manager for Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

METHOD OF PARTICIPATION

There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity. A statement of credit will be issued only upon receipt of a completed activity evaluation and will be emailed to you upon completion. You will receive your certificate from Med Learning Group.
If you have questions regarding the receipt of your certificate, please contact via email at [email protected].

ABOUT THIS ACTIVITY

Medical Learning Institute Inc and Med Learning Group are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of Medical Learning Institute Inc and Med Learning Group.
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute Inc or any of its partners, providers, and/or supporters.

RELEASED DATE: October 10, 2025
EXPIRATION DATE: October 10, 2026

Copyright © 2025 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.